Exploiting temporal aspects of cancer immunotherapy.
Rachael M ZemekValsamo AnagnostouInês Pires da SilvaGeorgina V LongWillem Joost LesterhuisPublished in: Nature reviews. Cancer (2024)
Many mechanisms underlying an effective immunotherapy-induced antitumour response are transient and critically time dependent. This is equally true for several immunological events in the tumour microenvironment induced by other cancer treatments. Immune checkpoint therapy (ICT) has proven to be very effective in the treatment of some cancers, but unfortunately, with many cancer types, most patients do not experience a benefit. To improve outcomes, a multitude of clinical trials are testing combinations of ICT with various other treatment modalities. Ideally, those combination treatments should take time-dependent immunological events into account. Recent studies have started to map the dynamic cellular and molecular changes that occur during treatment with ICT, in the tumour and systemically. Here, we overlay the dynamic ICT response with the therapeutic response following surgery, radiotherapy, chemotherapy and targeted therapies. We propose that by combining treatments in a time-conscious manner, we may optimally exploit the interactions between the individual therapies.
Keyphrases
- clinical trial
- papillary thyroid
- end stage renal disease
- stem cells
- chronic kidney disease
- radiation therapy
- minimally invasive
- early stage
- newly diagnosed
- squamous cell
- prognostic factors
- peritoneal dialysis
- coronary artery bypass
- single molecule
- patient reported outcomes
- insulin resistance
- brain injury
- combination therapy
- cerebral ischemia
- acute coronary syndrome
- bone marrow
- open label
- weight loss
- study protocol
- high density